Yahoo
NYSE - Nasdaq Real Time Price USD

ResMed Inc. (RMD)

231.71 -21.12 (-8.35%)
As of 1:14:24 PM EDT. Market Open.
Trade ResMed on Coinbase
RMD Q1 2027 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for RMD

What's happening with RMD?

11m ago
Powered by Yahoo Scout

ResMed delivered a stronger-than-expected fiscal first quarter, with $1.41 billion in revenueand non-GAAP EPS (earnings per share) of $2.91. Management maintained full-year guidance, while Astral’s discontinuation creates a roughly $75 million revenue headwind. RMD is down 8.14% in the current regular sessiondespite the earnings beat.

Powered by Yahoo Scout
  • Previous Close 252.83
  • Open 246.56
  • Bid 231.79 x 10000
  • Ask 232.21 x 30000
  • Day's Range 231.55 - 248.04
  • 52 Week Range 180.27 - 277.67
  • Volume 1,687,981
  • Avg. Volume 1,316,645
  • Market Cap (intraday) 32.588B
  • Beta (5Y Monthly) 0.75
  • PE Ratio (TTM) 22.22
  • EPS (TTM) 10.43
  • Earnings Date (est.) Jan 28, 2027
  • Forward Dividend & Yield 2.64 (1.04%)
  • 1y Target Est 251.52
  • Morningstar Rating Rating available with Stock Picks access

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

www.resmed.com

11,370

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RMD
3.02%
S&P 500 (^GSPC)
10.68%

1-Year Return

RMD
7.17%
S&P 500 (^GSPC)
11.05%

3-Year Return

RMD
73.63%
S&P 500 (^GSPC)
81.83%

5-Year Return

RMD
7.77%
S&P 500 (^GSPC)
64.51%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 1.41B
Earnings 418.41M
Profit Margin 29.57%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
500M
1B
27.0%
28.0%
29.0%

Analyst Insights

View More

Analyst Price Targets

175.00 Low
251.52 Average
231.71 Current
320.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/30/2026
Analyst Wells Fargo
Rating Action Maintains
Rating Equal-Weight
Price Action Raises
Price Target 215 -> 250

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    26.95%

  • Return on Assets (ttm)

    14.00%

  • Return on Equity (ttm)

    24.27%

  • Revenue (ttm)

    5.65B

  • Net Income Avi to Common (ttm)

    1.52B

  • Diluted EPS (ttm)

    10.43

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.47B

  • Total Debt/Equity (mrq)

    12.54%

  • Levered Free Cash Flow (ttm)

    939.25M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: